Effects of PAF Antagonist BN52021 on Systemic and Renal Oxidative Stress in Experimentally Induced Obstructive Jaundice
The aim of this study is to investigate the effects of PAF antagonist BN52021 on systemic and renal oxidative stress in experimentally induced obstructive jaundice. A total of 30 Wistar-Albino type rats used in the study were divided into sham, control and study groups, each consisting of ten subjects. A laparotomy was performed on the study and control groups, and the choledochus was ligated and dissected. In the sham group, the choledochus was dissected by laparotomy and not ligated. The subjects in the control group were administered physiological saline intraperiotoneally between the 2nd and 7th days, and subjects in the study group were administered BN52021 at a dose of 1 mg/kg/day. Blood and kidney samples were taken postoperatively on the 7th day. In the blood sample, bilirubine, SOD, GSH-PX, BUN, creatinine determination, and in renal tissue, MDA and histopathologic examination, were performed. Serum bilirubine, blood urea nitrogen, creatinine, renal and, within erythrocyte, MDA levels were all measured on the 7th day in the study and the working groups' levels were significantly higher than those in the sham group. In BN52021 administered subjects, except the billirubine parameter measured on the 7th day, other parameters were found to be significantly lower than in the control group. The administration of BN52021 brought about a significant rise in the levels of endogenous antioxidant, but it did not cause any significant change in renal hystopathologic scoring. The administration of BN52021 in experimental obstructive jaundice, improves renal functions by increasing endogenous antioxidant enzyme levels and by decreasing lipid peroxidation.
Effects of PAF Antagonist BN52021 on Systemic and Renal Oxidative Stress in Experimentally Induced Obstructive Jaundice
The aim of this study is to investigate the effects of PAF antagonist BN52021 on systemic and renal oxidative stress in experimentally induced obstructive jaundice. A total of 30 Wistar-Albino type rats used in the study were divided into sham, control and study groups, each consisting of ten subjects. A laparotomy was performed on the study and control groups, and the choledochus was ligated and dissected. In the sham group, the choledochus was dissected by laparotomy and not ligated. The subjects in the control group were administered physiological saline intraperiotoneally between the 2nd and 7th days, and subjects in the study group were administered BN52021 at a dose of 1 mg/kg/day. Blood and kidney samples were taken postoperatively on the 7th day. In the blood sample, bilirubine, SOD, GSH-PX, BUN, creatinine determination, and in renal tissue, MDA and histopathologic examination, were performed. Serum bilirubine, blood urea nitrogen, creatinine, renal and, within erythrocyte, MDA levels were all measured on the 7th day in the study and the working groups' levels were significantly higher than those in the sham group. In BN52021 administered subjects, except the billirubine parameter measured on the 7th day, other parameters were found to be significantly lower than in the control group. The administration of BN52021 brought about a significant rise in the levels of endogenous antioxidant, but it did not cause any significant change in renal hystopathologic scoring. The administration of BN52021 in experimental obstructive jaundice, improves renal functions by increasing endogenous antioxidant enzyme levels and by decreasing lipid peroxidation.
